* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Effects of Acute Exposure to PCBs 126 and 153 on Anterior Pituitary
Survey
Document related concepts
Bioidentical hormone replacement therapy wikipedia , lookup
Testosterone wikipedia , lookup
Hormone replacement therapy (menopause) wikipedia , lookup
Hormone replacement therapy (male-to-female) wikipedia , lookup
Hypothyroidism wikipedia , lookup
Hormone replacement therapy (female-to-male) wikipedia , lookup
Hypothalamus wikipedia , lookup
Hyperthyroidism wikipedia , lookup
Graves' disease wikipedia , lookup
Sexually dimorphic nucleus wikipedia , lookup
Growth hormone therapy wikipedia , lookup
Transcript
47, 158 –169 (1999) Copyright © 1999 by the Society of Toxicology TOXICOLOGICAL SCIENCES Effects of Acute Exposure to PCBs 126 and 153 on Anterior Pituitary and Thyroid Hormones and FSH Isoforms in Adult Sprague Dawley Male Rats D. Desaulniers, 1 K. Leingartner, M. Wade, E. Fintelman, A. Yagminas, and W. G. Foster Environmental and Occupational Toxicology Division, Bureau of Chemical Hazards, Environmental Health Directorate, Health Protection Branch, Department of Health, Ottawa, Ontario, Canada Received May 1, 1998; accepted October 5, 1998 3,3*,4,4*,5-Pentachlorobiphenyl (PCB 126) and 2,2*,4,4*,5,5*hexachlorobiphenyl (PCB 153) were administered to adult male rats in order to identify sensitive indicators of endocrine disruption. We tested the hypothesis that PCB exposure modifies folliclestimulating hormone (FSH) pituitary isoforms, as well as the pituitary and serum concentrations of FSH, luteinizing hormone (LH), growth hormone, prolactin, and thyroid-stimulating hormone (TSH). Effects on serum levels of thyroxine (T4) and testosterone (T), and prostate androgen receptor content, were also tested. In one experiment, 5 groups of 8 rats each received two ip injections, one day apart, of either corn oil or 6.25, 25, 100 or 400 mg/kg/day of PCB 126. Decreases ( p < 0.05) in the serum concentrations of T4 and LH started at doses of 25 and 100 mg/kg/day, respectively. Serum FSH concentrations were reduced ( p 5 0.07) in the highest dose group. In contrast, pituitary content of FSH and LH increased with PCB-126 doses ( p 5 0.004, p 5 0.002, respectively). Despite changes in reproductive hormones, PCB-126 had no effect on the androgen receptor content of the prostate. The effect of PCB-126 was tested in the hemicastrated rat, and suggested adverse effects on testosterone secretion. To test the effects of PCB exposure on FSH pituitary isoforms, 4 groups of 10 male rats received two ip injections, one day apart, of either corn oil, PCB 153 (25 mg/kg/day), estradiol-17b (E2; 20 mg/kg/day), or PCB 126 (0.1 mg/kg/day). Serum T4 levels were higher ( p < 0.01) in the E2 and PCB 153 groups, and slightly reduced in the PCB 126-treated groups, compared to controls. Simultaneous purification of pituitary FSH and TSH isoforms was performed by HPLC, using two chromatofocusing columns in series. In contrast to TSH isoforms, the distribution of FSH isoforms over the chromatography run differed slightly between treatment groups; the amounts of FSH isoform eluted during the pH gradient were lower ( p < 0.05) in E2 and PCB 153-treated rats than in control or PCB 126-treated rats. The similarity between the effects of E2 and PCB 153 on T4 and FSH isoforms supports the contention that PCB 153 possesses estrogenic properties. Serum LH and T4 concentrations were the most sensitive and practical endocrine indicators of PCBs 126 and 153 exposure in male rats. 1 To whom correspondence should be addressed at Room 330, Environmental Health Centre, Bldg # 8, Tunney’s Pasture, Postal Locator 0803D, Ottawa, Ontario, Canada K1A 0L2. Fax: 613–941– 4768. E-mail: [email protected]. Key Words: 3,3*,4,4*,5-pentachlorobiphenyl (PCB 126); 2,2*,4,4*,5,5*-hexachlorobiphenyl (PCB 153); follicle-stimulating hormone (FSH); thyroid-stimulating hormone (TSH); luteinizing hormone (LH); rat. The worldwide commercial production of PCBs essentially ceased in the late 1970s, and yet, more than 70% of the global production of PCBs is estimated to be still in use or in stock (Hileman, 1993). Humans continue to be exposed to PCBs because of their presence in “environmental hot spots,” their accidental release from disposal sites (Phaneuf et al., 1995), and their presence in our diet, due in part to the accumulation of PCBs in certain species of fish and seafood collected in the more contaminated areas (Hansen et al., 1995; Li and Hansen, 1997). Despite their gradual decline, PCBs remain the major contaminants of human tissues (Newsome et al., 1995), and thus, they still represent a major toxicological issue. Some PCBs and their metabolites have estrogenic (Connor et al., 1997; Soto et al., 1995) or antiestrogenic properties (Connor et al., 1997; Krishnan and Safe, 1993) and alter gonadotropin release from female rat pituitary cells in vitro (Jansen et al., 1993). PCBs alter thyroid functions in many ways (Brouwer et al., 1998). They indirectly favor thyroxine excretion by the activation of glucuronidating enzymes and by displacing thyroxine from transthyretin, the major transporting protein in rodents. They can also cause direct effects on the thyroid by inhibiting proteolysis of thyroglobulin (van Birgelen et al., 1995). PCB 126 (3,39,4,49,5-pentachlorobiphenyl), a CYP1A1 inducer, non-ortho substituted, is the most toxic PCB congener and has antiestrogenic properties (Krishnan and Safe, 1993). PCB 153 (2,29,4,49,5,59-hexachlorobiphenyl), is a diortho-substituted congener with CYP2B-inducing properties. It has been shown to have estrogenic effects in the rat (Li et al., 1994) and is one of the more highly concentrated PCB congeners found in human tissues (Foster, 1995; Newsome et al., 1995). Gonadotropins, luteinizing hormone, (LH); follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH), are glycoproteins present in multiple forms within the pituitary 158 ENDOCRINE EFFECTS OF PCBs 126 AND 153 gland and in circulation. Hormonal isoforms differ in their degree of glycosylation and sialylation (Baenziger and Green, 1988; Smith and Baenziger, 1988) and amino acid sequence (Gharib et al., 1990; Matthews et al., 1993; Ryan et al., 1987; Weiss et al., 1992; Wilson et al., 1990), which alter their half-lives, affinity for the receptors (Stanton et al., 1996), ability to activate different intracellular signal transduction systems (FSH, Arey et al.1997; TSH, Schaaf et al., 1997) and thus, their in vivo and in vitro biological activity (Beitins and Padmanabhan, 1991; Dahl and Stone, 1992; Hassing et al., 1993; Stanton et al., 1992; Wide and Bakos, 1993). Up to 20 pituitary isoforms of human FSH and 30 isoforms of human LH have been purified (Stanton et al., 1992, 1993). Different isoforms are secreted depending on the endocrine environment of the pituitary gland, and isoforms vary according to age, stage of reproductive cycle, and in certain types of infertility (Beitins and Padmanabhan, 1991; Dahl and Stone, 1992; Simoni et al., 1992; Hassing et al., 1993; Wide and Bakos, 1993). In the search for sensitive indicators of xenobiotic exposure, FSH isoforms may reveal another level of endocrine disruption where the quality, but not the quantity, of the hormone is affected. The measurement of circulating hormones is still an essential tool in diagnostic endocrinology. However, because of the dynamic nature of hormone secretion, measuring reproductive hormones during extreme endocrine conditions is useful for permitting the observation of endocrine disorders that could not be detected under normal conditions. Some examples include the comparison of endocrine events during the normal estrous cycle and following superovulatory treatment in mature animals (Desaulniers et al., 1995a,b) or in HCB-treated rats (Foster et al., 1993a). Others used a gonadotropin-releasing hormone treatment to reveal adverse effects of lead on LH and testosterone secretion in monkeys (Foster et al., 1993b). We tested the usefulness of the hemicastration model (Frankel and Mock, 1982; Frankel and Wright, 1982) in PCB-treated rat, with the objective of developing a sensitive in-vivo toxicological model to facilitate the detection of endocrine-disrupting effects. This in vivo model, not requiring the administration of exogenous hormones, provides insights to the integrity of the mechanisms regulating testosterone production and FSH secretion. The removal of one testicle creates an unusual endocrine compensatory effect, whereby the remaining testicle increases its testosterone output to match normal levels in circulation. In addition, hemicastration increases FSH concentrations in serum and pituitary, due to a reduction in inhibin levels (Brown and Chakraborty, 1991; Brown et al., 1991; Medhamurthy et al., 1995). Inhibin is secreted by both testes and inhibits FSH secretion, so the removal of one gonad decreases inhibin output. Thus, this experimental model tests the functionality of the hypothalamo-pituitary-testicular axis and should help to identify the primary site of toxic insults. Therefore, the acute endocrine-disrupting effects of PCB 126 were tested in adult male rats by measuring, in both the serum and the pituitary 159 gland, hormones that are involved in reproductive functions (LH, FSH, prolactin (PRL), and testosterone), development, metabolism (growth hormone (GH) and PRL), and thyroid function (TSH and thyroxine). In addition, the data generated by the PCB 126-treated, hemicastrated rat model, and the analysis of FSH isoforms in PCBs 126- and 153-treated male rats, were assessed as toxicological investigative tools. MATERIALS AND METHODS Animal treatments. Adult male Sprague Dawley rats (Charles River, St-Constant, Québec, Canada), weighing 390 – 422 g, and at approximately 90 days of age, were used for all experiments. In a preliminary experiment, the effects of anaesthetising rats using isoflurane inhalation (n 5 8) or sodium pentobarbital ip injection (n 5 7) were compared by measuring concentrations of LH, FSH, TSH, GH, and PRL in the serum and pituitary gland homogenates, and also testosterone and thyroxine in the serum. Both serum TSH (1.8 6 0.4 ng/ml vs. 2.4 6 0.2, p 5 0.07) and thyroxine (3.1 6 0.2 vs 4.0 6 0.4 ng/ml, p 5 0.05) were lower in the sodium pentobarbital group than in the isoflurane group. All other serum hormone concentrations were also slightly lower in the sodium pentobarbital group when compared to isoflurane-anesthetized rats. The reverse situation occurred for hormone concentrations measured in the pituitary gland homogenate. Although anesthesia, or the use of some anesthetic agents, does not always induce detectable endocrine alterations (Cohen et al., 1983; Praputpittaya and Kimura, 1987; Waddell and Bruce, 1984), isoflurane anaesthesia was selected for all other experiments because (1) LH pulses (Strutton and Coen, 1996) and testosterone (Bardin and Peterson, 1967; Cooper and Waites, 1974; Hirsh et al., 1981) could be suppressed by anesthesia, and our results showed that some hormone levels are either significantly or slightly higher in isoflurane- than in sodium pentobarbital-treated rats; (2) increasing the duration of the anesthesia could decrease hormone levels (Schultz et al., 1995; Strutton and Coen, 1996), and, in contrast to sodium pentobarbital, isoflurane was found to induce a more rapid anesthesia. This occurred within a similar time frame between rats, following initiation of the anesthetic treatment, and thus subjected rats to less stress; and finally (3) sodium pentobarbital can be metabolized by the liver enzymes that are induced by PCBs, which could lead to variable anesthetic response among PCB-treated rats. In one experiment, the dose-response effects of acute exposure to PCB 126 were tested. On day 0 of the experiment, the rats received an ip injection of either corn oil or PCB 126 in corn oil at different concentrations: 6.25, 25, 100 and 400 mg/kg bw (Table 2). After 24 h, the same dosing regime was repeated. Rats were anesthetized two days after the second dose and exsanguinated via the abdominal aorta (between 9:00 A.M. and noon). The pituitary gland, brain, liver, a sample of fat, the testicles, and the thyroid gland were dissected out, weighed, and frozen at 285°C. Since serum LH decreased at a PCB-126 dose of 100 mg/kg/day (Table 2) supporting the contention of pituitary effects, this dose was then used for all subsequent experiments. In a second type of experiment, the ability of PCB 126 to induce alterations of the hypothalamo-pituitary-testicular axis was further tested in hemicastrated rats (Table 3), to determine if this model would be a more sensitive method for detecting altered testosterone and FSH secretions. Intact rats were treated, as previously described, using 100 mg/kg bw of PCB 126 per day for two days, and then hemicastrated on day 3, to ensure that the compensatory endocrine changes would be occurring under the influence of the PCB treatment. The rats were hemicastrated under isoflurane anesthesia according to the protocol of Waynforth and Flecknell (1992). Briefly, the protocol entailed exposing the left testicle by making a midscrotal incision, and ligating the testicular and epididymal vessels to remove the left testicle and epididymis. The rats were necropsied and exsanguinated on the 4th and 6th days after hemicastration. In a third type of experiment, pituitary FSH and TSH isoforms were purified from PCB 126-treated rats, to test if they could provide sensitive indicators of 160 DESAULNIERS ET AL. TABLE 1 Peptide Hormone Double Antibody Radioimmunoassay Reagents a and Sensitivity b Assay LH FSH TSH GH PRL Iodination hormone Standard curve hormone rLH-I-9 AFP-10250C rFSH-I-8 AFP-11454B rTSH-I-9 AFP-11542B rGH-I-6 AFP-5676B rPRL-I-6 AFP-10505B rLH-RP-3 AFP-7187B rFSH-RP2 AFP-4621B rTSH-RP3 AFP-5512B rGH-RP-2 AFP-3190B rPRL-RP-3 AFP-4459B Primary antiserum Sensitivity ng/mL rLH-S-11 0.16 rFSH-S-11 AFP-C0972881 rTSH-RIA-6 AFP329691Rb rGH-S-5 1.2 rPRL-S-9 AFP-131581570 0.47 0.8 0.7 a The names of the reagents are preceded by NIDDK. The secondary precipitating antibody was an anti-rabbit IgG developed in goat (Sigma Immunochemicals, St-Louis, MO) for all peptide hormone assays, except for GH, which required a goat anti-monkey IgG (Antibodies Incorporated, Davis, CA). b Sensitivity is defined as the smallest dose of reference preparation always three standard deviations apart from the nonspecific binding. The serum volumes used in the assays were: LH and FSH 250 mL, PRL 100 mL, TSH 150 mL and GH 20 mL. exposure. To ensure that this experiment would have detectable effects, two additional groups of rats were given either 25 mg/kg bw of PCB 153 or 20 mg/kg bw of estradiol-17b in two doses over two days. These doses of estradiol and PCB 153 were selected because they have been reported to cause uterotrophic effects (Li et al., 1994). In this experiment, the thyroid glands were dissected out, fixed, and examined for histological effects. Assays. Gonadotropin, PRL, GH and TSH concentrations were determined by double antibody radioimmunoassays (RIA). The method of iodination (Lussier et al., 1994) and assay procedures were as previously described (Desaulniers et al., 1997). Assay reagents and sensitivities are described in Table 1. Commercial double antibody, or coated tube, I 125 RIA kits (ICN Biomedicals, Costa Mesa, CA) were used for the measurement of testosterone, thyroxine, and triiodothyronine (T3). Ethoxyresorufin (EROD) and pentoxyresorufin o-deethylase (PROD) activities in 10 000 3g liver homogenate supernatants were determined on a Perkin-Elmer model LS50B fluorescence spectrometer equipped with a micro-plate reader, according to the method of Burke et al., (1985). PROD and EROD hepatic activities were calculated from the slope of the linear portion of the reaction. Chromatofocusing on HPLC. All the buffers contained 1% glycerol (Kojima et al., 1995; Stumpf et al., 1992). Pituitary gland homogenates were prepared, on ice, just before HPLC analysis. The glands were sonicated in vials containing 200 ml of 0.05 M phosphate-buffered saline, 1% BSA and several protease inhibitors (1 mM EDTA, 1.0 mM pepstatin A, 10 mM E-64, 17 mM 2,3-dehydro-2-deoxy-n-acetylneuraminic acid and 1.5 mg/ml aprotinin, Sigma Chemicals, St. Louis, MO). The homogenates were microcentrifuged at 1300 g for 30 min at 4°C (Model 5415C, Brinkmann Instruments, Rexdale, Ontario, Canada), and the supernatants were kept on ice. The sonication and centrifugation procedures were repeated two more times to obtain a final homogenate volume of 0.6 mL. These steps were sufficient to recover 99.2 % of the FSH. Preliminary experiments showed that additional sonication and recentrifugation of the pituitary pellet extracted only 0.8% of total immunoassayable FSH. The homogenates were prepurified and at the same time reconstituted in 0.025 M methylpiperazine (pH 5.7) buffer by using gel filtration (PD-10 disposable column, Pharmacia Biotech, Montréal, Quebec, Canada). Relative to the amount of FSH applied to the PD-10 column, 78.4 6 1.8 % of the FSH (n 5 17) was recovered in a pool of 1.5 ml eluting after an initial volume of 2 mL. Of this 1.5 ml eluate, 1 ml was applied to the HPLC column. The HPLC system (System Gold, Beckman) was equipped with a UV detector (model 166) set at 280 nm, a flow-through pH detector (Pharmacia Biotech), a fraction collector (Isco, Foxy) and two chromatofocusing columns (mono-p HR 5/5 and 5/20, Pharmacia Biotech) in series. The columns were equilibrated with start buffer (0.025 M methylpiperazine/HCl at pH 5.7), and the homogenate was injected. A pH gradient was developed for 65 min by eluting the columns with polybuffer-74 (Pharmacia Biotech) diluted 1:8 with water and adjusted to pH 4 with HCl. This was followed by a NaCl gradient (0 to 2 M) for 30 min and then elution of the columns with 2 M NaCl for 10 min. Fractions (one per minute for 110 min) were collected in 133100-mm borosilicate test tubes containing 200 ml of stabilizing buffer (0.5 M phosphate-buffered saline containing 3.5% BSA and the protease inhibitors already described), and then kept at 215°C for assay within 3 days of their elution. The total amount of FSH recovered from the HPLC fractions was determined to be 79.4 6 3.0% (n 5 18) of the amount applied to the HPLC column. Histology of the thyroid gland. Thyroids were fixed in 10% neutral buffered formalin and embedded in paraffin. Longitudinal sections (6 mm thick) were cut at a depth of 450 mm into the gland. None of the histological measurements were taken from the peripheral inactive follicles (Ness et al., 1993). The colloid vacuolation was analysed (magnification 5 2003) by categorizing 300 to 400 follicles per rat into five levels of vacuolation (1 5 no vacuoles, 2 5 less than 20% of the colloid area covered with vacuoles, 3 5 20 to 50% covered, 4 5 more than 50% covered, and 5 5 foamy colloid). All other histological analyses were performed objectively using the Optimas computer-imaging system (Bioscan, Edmonds, WA). The colloid density was analyzed (magnification 5 2003) using luminescence readings (0 5 white; 255 5 black). The colloid vacuolation and density were analyzed using preparations treated with periodic acid Schiff’s reagent which stains for carbohydrates. The epithelial height was measured from an average of 34 follicles per rat (magnification 5 10003), and follicle areas were calculated using the gray binary system, from an average of 14 follicles per rat (magnification 5 4003). The epithelial heights and follicle areas were taken from preparations treated with VanGieson’s stain for collagen. Data analysis. To test for differences in the elution pattern of FSH and TSH isoforms induced by the PCB or the estradiol treatments, the data was analyzed for each rat and the peaks of hormone, easily identifiable among rats, were used as markers of chromatographic regions containing isoforms with similar retention times. These regions were called isoform groups 1 to 6 for TSH, and 1 to 9 for FSH (Fig. 1). For the statistical analysis, the concentration of each hormone per fraction was expressed as a percentage of the total amount of hormone eluted during the whole chromatography run, and the percentages were added for each isoform group. The large amount of FSH eluted in isoform group 9 (see Fig. 2) prevented the data from reaching homogeneity of variance, even after arcsin transformation. Thus, 2 two-way analysis of variance (ANOVA) tests were used to analyze the isoform data. First, a two way ANOVA was performed, excluding the data from isoform group 9, testing the effects of treatment, isoform group, and treatment 3 isoform group interaction. Then differences in the overall treatment means of isoform groups 1 to 8 were assessed by the Duncan’s multiple range test. A second two-way ANOVA was performed, testing for an effect of treatment, isoform groups, and their interaction, using the amount of FSH eluted from the combined isoform groups 1 to 8 against that eluted in isoform group 9 (inset Fig. 2). For all other analyses, homogeneity of variance between dose groups was verified by O’Brien and Brown-Forsythe tests (SAS Institute Inc, 1992), and the data was log transformed, if required. The data were analyzed using ANOVA, with the model indicated in footnotes of the data table. Effects were considered significant at p # 0.05 and a tendency was indicated by p # 0.1. ENDOCRINE EFFECTS OF PCBs 126 AND 153 161 concentration (Table 2). There was a tendency for FSH concentrations to be lower in rats treated with the highest dose of PCB 126 compared with controls ( p 5 0.07, Table 2). Serum thyroxine concentrations decreased in rats treated with 25 mg/kg/day of PCB 126 or more ( p 5 0.0001), but this was not associated with significant changes in TSH concentrations (Table 2). In contrast to the decreasing concentrations of LH and FSH observed in the serum, the content of LH ( p 5 0.002) and FSH ( p 5 0.004) increased in the pituitary gland of rats treated with PCB-126 (Table 2). None of the doses of PCB 126 altered the cytosolic or the nuclear androgen receptor content of the prostate (Table 2). Experiment 2 Alterations of the hypothalamo-pituitary-testicular axis induced by a dose of 100 mg/kg/day of PCB 126 was further tested in hemicastrated rats (Table 3). In contrast to Experiment 1, body weight gain was decreased ( p 5 0.005) by the PCB 126 (100 mg/kg/day)-treatment in hemicastrated rats (PCB treated: 7 6 5 g; untreated: 27 6 4 g); note that the delay FIG. 1. HPLC chromatofocusing run for the separation of TSH and FSH isoforms from two pituitary glands. (A) Changes in pH detected by the flow through electrode and the gradient of NaCl during the chromatography run. (B) TSH and (C) FSH concentrations in each of the 0.5 mL fractions collected every minute during the run. Isoforms with similar retention times, easily identifiable between rats, were divided into 6 regions for TSH (B) and 9 regions for FSH (C). Rats 17 and 31, both treated with PCB 153, were selected to show an inter-individual difference observed in 8/20 rats, regardless of the treatment group. This difference is the presence of FSH eluting in the region 2 of the chromatogram in rat 31 (C). Effects of treatments are illustrated in Figure 2. RESULTS Experiment 1 Body weight gain declined in rats that received 100 mg/kg/ day of PCB 126 but this effect was only significant in the rats given a dose of 400 mg/kg/day (Table 2). Even at the highest dose, this effect on growth could not be associated with a statistically significant effect on GH, although the variability and the mean concentration of serum GH decreased (Table 2). The smallest dose of PCB 126 (6.25 mg/kg/day) significantly increased hepatic EROD activity, which reached maximal induction at a dose of 100 mg/kg/day. Serum LH concentrations decreased ( p 5 0.004) in rats treated with 100 mg/kg/day, but it was not associated with a significant change in testosterone FIG. 2. Amount of FSH eluted during intervals of the pH and NaCl gradients of the HPLC-chromatofocusing run in relation to the treatment groups. The amounts of FSH (mean 6 SE; n 5 5) are expressed as a percentage of the total amount of FSH eluted during each chromatography run. A two-way ANOVA on arcsine transformed data from the first 8 regions revealed a significant effect of pH interval ( p 5 0.0001) and treatment ( p 5 0.0001) with no significant interaction. Asterisks beside the legends indicate that the amount of FSH eluted during region 1– 8 in estradiol and PCB 153-treated rats, is smaller than in control rats ( p , 0.05, Duncan’s multiple range test). This can also be observed in the inset which illustrates the effects of a Treatment 3 Isoform group interaction ( p 5 0.02), the effects of treatment (p . 0.05) and isoform group (groups 1– 8 vs 9; p , 0.0001), derived from a second two-way ANOVA comparing the combined isoform groups 1– 8 to group 9. 162 DESAULNIERS ET AL. TABLE 2 Effects of Acute Exposure to PCB 126 on Body Weight Gain and Hepatic Ethoxyresorufin-o-deethylase Activity, Hormone Concentrations in the Serum and the Pituitary Gland, and Androgen Receptor Content of the Prostate Intraperitoneal doses of PCB 126 (mg/kg/day) 0 6.25 25 Body weight gain and hepatic ethoxyresorufin-o-deethylase (EROD) activity: Weight gain (g) 16.6 6 3.0 a 17.4 6 2.8 a 18.4 6 1.5 a d c EROD (nm/min/mg) 0.03 6 0.00 1.34 6 0.1 2.80 6 0.32 b Hormone concentrations in the serum: LH (ng/mL) 0.75 6 0.15 a 0.62 6 0.12 a 0.62 6 0.1 a T (ng/mL) 2.42 6 0.65 1.32 6 0.34 1.98 6 0.84 FSH (ng/mL) 11.88 6 0.87 9.85 6 0.84 11.11 6 0.94 TSH (ng/mL) 2.4 6 0.18 2.13 6 0.27 2.97 6 0.59 T4 (mg/dL) 3.95 6 0.35 a 3.48 6 0.31 ab 2.78 6 0.17 bc T3** (ng/dL) 72.8 6 3.9 a 79.4 6 4.1 a 67.8 6 5.5 ab GH (ng/mL) 29.9 6 14.4 24.1 6 6.2 32.8 6 19.0 PRL (ng/mL) 8.1 6 1.41 8.16 6 1.35 9.18 6 2.19 Hormone concentrations in the pituitary gland (relative to the wet weight of the gland): LH (ng/mg) 753 6 80 b 1139 6 188 a 1439 6 103 a c bc FSH (ng/mg) 337 6 46 416 6 47 580 6 36 a TSH (ng/mg) 596 6 75 544 6 73 789 6 94 GH (mg/mg) 54.4 6 9.9 61.7 6 9.2 64.1 6 4.8 PRL (ng/mg) 414 6 67 494 6 87 603 6 94 Androgen receptor content (fmole/mg protein) of the prostate: Cytosol 5.1 6 1.0 5.1 6 1.5 5.6 6 1.7 Nuclear 15.6 6 1.6 12.8 6 1.2 15.0 6 2.2 100 400 p value* 12.6 6 2.2 a 4.07 6 0.19 a 27.2 6 3.6 b 3.81 6 0.14 a 0.0001 0.0001 (log) 0.28 6 0.03 b 1.75 6 0.55 9.57 6 1.01 3.33 6 0.39 2.48 6 0.29 c 55.3 6 3.2 b 42.0 6 16.0 8 6 1.23 0.29 6 0.03 b 1.18 6 0.37 8.55 6 0.84 2.34 6 0.49 1.26 6 0.12 d 42.7 6 1.3 c 8.0 6 2.0 8.02 6 1.4 0.004 0.57 0.07 0.23 (log) 0.0001 0.0001 (log) 0.47 0.98 1374 6 156 a 528 6 56 ab 719 6 87 68.1 6 3.8 452 6 39 1508 6 101 a 513 6 34 ab 700 6 66 69.6 6 4.1 459 6 47 0.002 0.004 0.17 0.55 0.39 8.8 6 1.4 16.0 6 3.2 6.0 6 1.3 11.8 6 1.3 0.83 0.34 Note. T, testosterone; T4, thyroxine; T3, triiodothyronine. * p value from a one way ANOVA. Mean 6 standard error of the mean, n 5 8 rats/group. a,b,c,d One way ANOVA followed by Duncan’s multiple range test; means with different letters are significantly different (p , 0.05). ** Analyzed during revision. between PCB treatment and euthanasia was longer than in Experiment 1. Except for the reduced concentration of thyroxine, no other significant hormonal differences between hemicastrated groups were induced by the PCB-126 treatment (Table 3). The testosterone, LH, FSH and TSH concentrations were also compared with those of intact rats (see Table 2), not treated or treated with the same dose of PCB 126. In all cases, the data was compared using a two way ANOVA to test for effects of hemicastration, PCB treatment, and their interaction, followed by multiple comparison procedures (see Table 3). In contrast to the reduced LH concentration induced in intact rats by dosages of 100 mg/kg/day of PCB 126 compared to controls ( p , 0.05, Table 2), the PCB 126-treated, hemicastrated rats had the highest LH concentration, which was statistically higher than the PCB 126-treated intact rats but was not statistically higher than control intact rats (Table 2) or hemicastrated, untreated rats (Table 3). The elevated LH concentration in the PCB 126-treated, hemicastrated rats is associated with the lowest concentration of testosterone, which was statistically lower than in the normal rats (Table 2) but not in the untreated, hemicastrated rats (Table 3). FSH concentrations in hemicastrated rats (Table 3) and in the intact rats (Table 2) were not affected by the PCB-126 treatment. Hemicastration slightly increased FSH concentrations, since the PCB-treated and -untreated, hemicastrated rats (n 5 24, 12.3 6 0.6 ng/mL, Table 3) had a tendency for higher ( p 5 0.1) FSH concentrations than those measured in PCB treated and untreated intact rats (n 5 16, 10.7 6 0.7 ng/mL; Table 2). Hemicastration had no effect on TSH concentration (Table 3), whereas the 100 mg/kg/day PCB-126 treatment increased ( p 5 0.01) the TSH concentrations in the combined intact (Table 2) and hemicastrated (Table 3) rats. Experiment 3 Rats treated with PCBs 153 and 126 had elevated ( p 5 0.0001) PROD and EROD hepatic activity, respectively (Table 4). In all treatment groups, circulating levels of FSH, LH, TSH and testosterone were lower than in controls, although the difference was significant only for LH ( p 5 0.04). Thyroxine concentrations were significantly higher in the estradiol- and PCB 153-treated rats than in controls. The estradiol treatment decreased pituitary concentrations of FSH but increased those of prolactin (Table 4). Although thyroxine was not significantly lower in the PCB 126-treated group than in the control group (Table 4), the colloid of the thyroid follicles was less dense (colloid density: luminescence units higher) in the PCB 126-treated rats than in the controls (Table 5). 163 ENDOCRINE EFFECTS OF PCBs 126 AND 153 TABLE 3 Effects of Acute Exposure to PCB 126 on Hormonal Serum Concentrations in Hemicastrated Male Rats Hormonal serum concentrations a HC HC 1 PCB 126 100 mg/kg/day Testosterone b (ng/mL) LH c (ng/mL) FSH d (ng/mL) TSH e (ng/mL) Thyroxine (mg/dL) Prolactin (ng/mL) GH (ng/mL) 1.42 6 0.45 0.6 6 0.07 12.18 6 0.8 2.31 6 0.34 3.68 6 0.38 11.85 6 2.2 8.97 6 2.65 0.76 6 0.15 0.83 6 0.13 12.49 6 1.1 3.14 6 0.34 1.62 6 0.17* 7.89 6 1.4 13.63 6 3.0 Note. HC, hemicastrated; mean 6 standard error of the mean, 12 rats/group. * Significantly lower than hemicastrated rats (t-test, p 5 0.0001). a The rats were hemicasterated 48 h following the second i.p. injection of vehicle (corn oil) or PCB 126. Necropsy occurred 4 and 6 days following hemicastration. b The testosterone, LH, FSH and TSH concentrations were also compared with those of intact rats (see Table 2), not treated or treated with the same dose of PCB 126 as above. In all cases, the data was compared using two way anova to test for effects of hemicastration, PCB treatment and their interaction, followed by all pairwise multiple comparison procedures (Student-Newman-Keuls method), unless indicated otherwise. Testosterone analysis using log transformed data: effect of hemicastration ( p 5 0.04), and a tendency for an effect of PCB 126 ( p 5 0.09). The concentration in the hemicastrated-PCB treated group (0.76 ng/mL) is lower than in the intact control group (2.42 ng/mL, Table 2, Mann-Whitney Rank Sum Test, p 5 0.01). c LH analysis using log transformed data: effect of hemicastration ( p 5 0.05), and an effect of hemicastration 3 PCB 126 interaction ( p 5 0.003). The intact rats treated with PCB 126 (see Table 2) had a lower ( p , 0.05) concentration of LH than the untreated intact rats or both groups of hemicastrated rats. d FSH analysis on the raw data: there is a tendency ( p 5 0.10) in hemicastrated (PCB treated or not) rats to have higher FSH concentrations than in intact (PCB treated or not, Table 2) rats. e TSH analysis on the raw data: effect of PCB 126 ( p 5 0.01) with higher concentrations measured in PCB treated rats. TSH and FSH isoforms were separated into 6 and 9 chromatographic regions of similar retention times among rats (Fig. 1). The reproducibility of the technique is shown by the overlap of the pH, TSH and FSH profiles between rat samples (Fig. 1). A peak of FSH isoforms eluted between pH 5.25 and 4.5 in 8/20 rats, regardless of the treatment group, indicated interindividual differences in isoform distribution (Fig. 1). The average amount of FSH eluted during separate chromato- TABLE 4 Effects of Acute Exposure to Estradiol-17b, PCB 126 or PCB 153 on Body Weight Gain, Hepatic Ethoxy- and Pentoxy-Resorufin-o-Deethylase Activity, and the Hormone Concentrations in the Serum and in the Pituitary Gland Control (oil) Estradiol-17b PCB 153 Body weight gain* and hepatic ethoxy (EROD)** and pentoxyresorufin-o-deethylase (PROD)** activity: Weight gain (g) 20.4 6 2.9 18.0 6 2.8 16.8 6 1.6 EROD (nm/min/mg) 0.19 6 0.01 c 0.18 6 0.01 c 0.46 6 0.05 b PROD (nm/min/mg) 0.3 6 0.05 c 0.25 6 0.03 c 3.12 6 0.25 a Hormone concentrations in the serum:** LH (ng/mL) 0.55 6 0.1 a 0.31 6 0.08 b 0.28 6 0.04 b T (ng/mL) 3.22 6 0.38 2.07 6 0.5 2.32 6 0.54 FSH (ng/mL) 9.54 6 0.55 7.63 6 0.92 8.4 6 0.49 TSH (ng/mL) 2.67 6 0.64 1.69 6 0.27 1.53 6 0.23 T4 (mg/dL) 4.43 6 0.36 b 5.6 6 0.26 a 5.27 6 0.33 a Hormone concentrations in the pituitary gland (relative to the wet weight of the gland):**** LH (ng/mg) 849 6 119 857 6 80 984 6 52 FSH (ng/mg) 382 6 26 a 299 6 19 b 409 6 28 a TSH (ng/mg) 792 6 97 648 6 110 724 6 78 GH (mg/mg) 48 6 10 60 6 6 72 6 7 PRL (ng/mg) 480 6 70 b 1160 6 152 a 626 6 58 b PCB 126 p value*** 17.3 6 1.4 12.8 6 1.04 a 0.48 6 0.04 b 0.71 0.0001 (log) 0.0001 (log) 0.25 6 0.04 b 2.26 6 0.48 8.27 6 0.65 1.42 6 0.12 3.81 6 0.2 b 0.04 0.37 0.26 0.08 0.0004 1070 6 155 438 6 36 a 785 6 59 56 6 7 796 6 134 b 0.37 (log) 0.005 0.67 0.14 0.002 Note. T, testosterone; T4, thyroxine. Mean 6 standard error of the mean. *: n 5 4 rats/group. **: n 5 10 rats/group. ***: p value for a one way anova. ****: Control n 5 6. Estradiol-17b, 0.02 mg/kg/day, n 5 10. PCB 153, 25 mg/kg/day, n 5 10. PCB 126, 0.1 mg/kg/day, n 5 7. a,b,c : One way ANOVA followed by Duncan’s multiple range test; means with different letters are significantly different ( p , 0.05). 164 DESAULNIERS ET AL. TABLE 5 Histology of Thyroid Glands after Treatments Treatment groups Measurements Epithelial height mm Follicle area mm 2 Colloid density (Luminescence unit) CTRL (9) a E2 (10) PCB126 (9) PCB153 (9) 11.1 6 0.2 b (242) c 891.1 6 61.9 (144) 76.3 6 1.4 (899) 11.6 6 0.1 (346) 1140.6 6 121.4 (109) 79.9 6 1.3 (1043) 12.0 6 0.1 (311) 866.8 6 65.4 (128) 93.9 6 1.0* (1049) 11.4 6 0.1 (370) 827.4 6 66.7 (131) 89.8 6 1.5 (895) Percent area of colloid occupied with vesicles Colloid vacuolation 0%: ,20%: 20–50%: .50%: Foamy follicles Number of follicles (%) 50.6 6 6.3 13.4 6 2.4 5.2 6 1.3 4.5 6 1.4 26.4 6 4.6 56.8 6 5.6 12.3 6 2.2 4.1 6 1.3 1.7 6 0.7 25.2 6 3.9 56.4 6 10.2 11.8 6 2.7 2.3 6 0.8 1.2 6 0.5 28.2 6 9.9 56.2 6 5.5 17.2 6 3.1 1.5 6 0.5 3.0 6 2.1 22.0 6 4.7 * Significantly different from control ( p 5 0.048). Analyzed by ANOVA and Duncan’s multiple range test with the rat nested in the treatment group as random error (Littell et al., 1991). a Number of rats per group. b Mean 6 standard error. c Number of observations. graphic regions or isoform groups, is presented in Figure 2 for each treatment group,. It indicates that approximately 70% of the total FSH eluted between 1–2 M NaCl. Two way ANOVA over the first eight isoform groups (treatment p 5 0.0001; isoform p 5 0.0001; interaction p . 0.05), followed by a Duncan’s multiple comparison test among treatment groups, demonstrated that a lower amount of FSH eluted in E2 and PCB 153-treated rats ( p , 0.05) than in control and PCB 126-treated rats (this can be observed from the asterisks beside the legends and the inset of Fig. 2). The data is presented as a percentage of the hormone eluted during the whole chromatographic run (Fig. 2); thus, a treatment decreasing the amount of FSH over the first eight isoform groups will necessarily increase the amount of FSH in group 9. This effect is demonstrated by a significant treatment 3 isoform group interaction ( p 5 0.02) when the amount of FSH eluted over the first eight isoform groups is compared with that of the ninth group (inset Fig. 2). The other effects in the model were isoform group ( p 5 0.0001) and treatment ( p . 0.05). No effects could be detected for the TSH isoforms; however, the chromatofocusing technique was only optimized for the separation of FSH isoforms, not TSH isoforms. DISCUSSION The effects of acute exposure to PCB 126 were assessed by measuring the dose response on serum and pituitary hormone levels in intact rats. In order to search for more sensitive indicators of endocrine effects, hormones were also measured in hemicastrated rats, and the pituitary isoforms of FSH and TSH were studied. Our results demonstrate that circulating LH and thyroxine concentrations in the intact adult male rat were the most easily obtainable and sensitive endocrine indicators of PCBs 126 and 153 exposure. The approaches of studying hemicastrated rats and the pituitary isoforms were useful in further characterizing the effects of PCB 126 and PCB 153. PCB-126 treatment decreased thyroxine (Tables 2, 3, and 4) and T3 concentrations in a dose related manner (Table 2). Despite this, there were no feedback responses leading to a dose-response increase in TSH concentration (Table 2). This is not an unusual observation in PCB-treated rats (Barter and Klaassen, 1994; Liu et al., 1995; Morse et al., 1996). Therefore, this leads to the suggestion that, in addition to interfering with the thyroid gland, thyroid hormone transport, and metabolism (Brower et al., 1998), PCBs would also interfere with the hypothalamo-pituitary axis (Brower, 1998). Exposure to coplanar PCBs or to 2,3,7,8-tetrachlorodibenzodioxin is known to alter TSH concentrations (Kohn et al., 1996; Seo et al., 1995) but serum TSH response is not always predictable (Capen, 1995; Morse et al., 1996). The slight increase in TSH induced by 100 mg/kg/day of PCB 126 (Tables 2 and 3) contrasts with the non-significant reduction in TSH concentration observed in Table 4. Studying the endocrine events through time following ENDOCRINE EFFECTS OF PCBs 126 AND 153 acute exposure to PCBs could provide the information which would explain the apparent inconsistencies (Tables 2 and 3 vs. Table 4) in the trends of the TSH responses. Both estradiol and PCB 153 increased thyroxine concentrations (Table 4). This effect of estradiol could be explained by the fact that estradiol is known to regulate thyroid-releasing hormone (TRH) gene expression (Croissandeau et al., 1996), 59-iodothyronine deiodinase activities (Lisboa et al., 1997), up-regulates the TRH receptor (Kimura et al., 1994) and, with striking efficiency, decreases the activity of the adenohypophyseal TRH-degrading ectoenzyme, which is restored in 24 – 48 h following the injection (Schomburg and Bauer, 1997). Estrogenic xenobiotics are known to alter thyroid hormones in male rats (Gray Jr. et al., 1989; Li and Hansen, 1997), in accordance with the PCB 153-induced increase in thyroxine concentrations (Table 4), which might be attributed to its estrogenic properties (Li et al., 1994). In accordance with our observations, PCB 153 administration to pregnant rats (64 and 16 mg/kg/day on days 10 –16 of gestation) slightly increased thyroxine concentration at weaning ( p 5 0.058, Ness et al., 1993). Also, 5 mg/kg bw per day of Aroclor 1254 on Days 10 to 16 of gestation induced a small, but statistically significant increase in thyroxine concentration in the adult male offspring on postnatal day 90 (Morse et al., 1996). In that study, PCB 153 was a predominant congener measured in the maternal and fetal plasma and in the fetal brain. In prepubertal female rats PCB 153 slightly increased thyroxine concentration at low dose of exposure preceded by a slight decline with increasing doses (Li et al., 1994). Despite this, using experimental models different from ours, PCB 153 has usually been found to decrease thyroxine concentration (Ness et al., 1993; Morse et al., 1996; van Birgelen et al., 1992). The histological analysis of the thyroid glands only revealed that the colloid is less dense in PCB 126-treated rats than in the controls (Table 5), suggesting mobilization of glandular thyroid hormones to delay systemic hypothyroidism (Hansen et al., 1995) facilitated by coplanar PCB activated hepatic enzymes (Chu et al., 1994; Desaulniers et al., 1997; Kohn et al., 1996; Seo et al., 1995). Important changes in thyroid histology are usually associated with significant changes in TSH levels (Liu et al., 1995), so our histological observations are in accordance with the absence of statistically significant changes in TSH concentrations (Table 4). Collectively, the indicators of thyroid function from the PCBs 126- and 153-treated rats support the idea that measurement of the thyroxine concentration is the most sensitive endocrine indicator of PCB exposure (Gray Jr. et al., 1993) and is more rapid than histological assessment of the thyroid gland. Although the hemicastrated rat model was unsuccessful at increasing the sensitivity of hormone measurements to assess endocrine-disrupting effects, the combined results from the PCB 126-intact and -hemicastrated rats (Tables 2 and 3) suggest that PCB 126 affected the endocrinology of the reproductive system by acting at both the hypothalamo-pituitary axis 165 and the testicle. Although LH concentrations in intact PCB 126-treated rats were significantly reduced and testosterone concentrations were not, both hormones showed a decrease. This suggests that the hypothalamo-pituitary axis is a site of PCB-126 toxic insult and that PCB 126 may have had little effect on testicular responsiveness to LH stimulation. The low testosterone concentrations despite slightly elevated LH levels in hemicastrated PCB 126-treated rats, suggest a decrease in testicular responsiveness to LH stimulation, similar to that previously characterized in TCDD-treated male rats (Cooke et al., 1998; Moore et al., 1985; Ruangwises et al., 1991; ). In contrast to the absence of TSH response to the decrease in thyroxine (Table 2), the hemicastrated rat model suggests that the PCB-126 treatment did not inhibit the hormonal feedback regulatory system of the hypothalamo-pituitary-testicular axis. Indeed, the PCB-126 treatment decreased LH secretion in intact rats (Table 2), but it was unable to reduce the LH serum concentrations in PCB-treated, hemicastrated rats, probably because this latter group had the lowest concentration of testosterone (Tables 2 vs 3), and thus, a reduced negative feedback regulation of LH secretion at the hypothalamo-pituitary level. Also, the PCB-126 treatment did not prevent a compensatory increase in FSH, which resulted from the diminished negative regulatory feedback induced by lower concentrations of inhibin created by the removal of one testicle. The hemicastrated rat offers a useful in vivo model for the characterization of toxic insults to the hypothalamo-pituitary-testicular axis. To improve the use of this in vivo model in reproductive toxicology, detailed time course studies of the endocrine events following hemicastration must be done to identify the important time points at which the relationship between FSH and inhibin, and testosterone and LH, should be assessed. The present study represents the first attempt to characterize changes in isoforms of pituitary hormones in response to toxic exposure. The small, but statistically significant, decreases in the amount of FSH eluted during the pH gradient (Fig. 2; isoform groups 1– 8) induced by estradiol and PCB 153, compared to control and PCB 126-treated rats, suggest that a small percentage of the FSH molecules in the pituitary gland were altered, causing them to attach more tightly to the HPLC column. This led to an increase in the proportion of FSH isoforms eluted under the high NaCl concentration gradient (1–2 M), which were confirmed by other investigators to be the more acidic isoforms (Keel and Schanbacher, 1987). In other species, the effects of estradiol on circulating hormone and FSH isoforms have been reported to be similar to those documented here. In men, estradiol treatment reduced circulating LH and testosterone concentrations (Cemeroglu et al., 1997; Veldhuis and Dufau, 1993) and in castrated rams, exogenous estrogen induced a marked increase in the acidic forms of ovine pituitary FSH eluting during the NaCl peak (Keel and Schanbacher, 1987). Both PCBs 126 and 153 decreased circulating LH concentrations (Tables 2 and 4), and yet, only PCB 153 changed the distribution of FSH isoforms (Fig. 2). The 166 DESAULNIERS ET AL. explanation might involve different mechanisms through which PCBs exert their effects. PCB 153 and PCB 126 are known to induce different tissue responses, in particular, on the activation of hepatic enzymes (Table 3; Li and Hansen, 1997), and also on intracellular Ca21 homeostasis (Seegal et al., 1990; Shain et al., 1991; Kodavanti et al., 1993; Maier et al., 1994; Wong et al., 1997), which highly controls gonadotropinreleasing hormone (GnRH) neurons (Conn, 1996). GnRH is a major regulator of gonadotropin production (Evans et al., 1996), and of the secretion of specific LH and FSH isoforms in humans (Matikainen et al., 1992; Phillips and Wide, 1994; Zambrano et al., 1995), but not in all animals (Hassing et al., 1993). The approach of studying FSH isoforms, although labor intensive, could be more sensitive than measuring the circulating and the pituitary levels of FSH, since they were not significantly affected by PCB 153 exposure (Table 4). Alteration of the distribution of FSH pituitary isoforms suggests another level of endocrine disruption where the quality, rather than the quantity, of FSH was affected. Whether the slight changes in the relative proportions of the FSH pituitary isoforms reflect changes in immunoreactive FSH fragments within the pituitary, or if these changes lead to significant and biologically relevant alterations in the circulating isoforms, remains to be investigated. The measurement of the pituitary gland content of the hormones provided additional insights for the mechanisms of the hormonal effects. The increased pituitary content of LH (even at the smallest dose of PCB 126) and FSH in PCB 126-treated rats (Table 2), associated with lower circulating levels, supports PCB 126-induced alteration of the secretory mechanisms of the gonadotroph cells. The lower pituitary content of FSH in estradiol treated rats (Table 4), in the absence of an increased circulatory level, suggests a decreased synthesis of FSH. Estradiol is also known to increase the transcription and secretion of PRL (Lamberts and MacLeod, 1990) and indeed, estradiol treatment increased pituitary PRL content in the present study (Table 4), as did the synthetic estrogen, diethylstilbestrol, when administered to immature female rats (Wade et al., 1997). In conclusion, estradiol, PCB 126 and PCB 153 alter several endocrine parameters, probably, through different mechanisms. All three compounds decreased LH secretion, whereas only estradiol and PCB 153 slightly altered FSH isoforms. The mechanism of action of estradiol could be dissociated from that of PCB 153, since estradiol decreased FSH pituitary content and increased pituitary prolactin, but, in contrast to both PCBs, it had no effect on hepatic enzymes. In regard to thyroid function, PCB 126 decreased thyroxine concentration, whereas both estradiol and PCB 153 slightly increased thyroxine concentration. The use of the hemicastrated rat model and the study of pituitary FSH isoforms were labor-intensive and not useful in providing more sensitive indicators of endocrine disruption, yet they permitted further characterization of the effects of these xenobiotics. The PCB 126-treated, hemicastrated rat model supported a testicular deficiency in PCB 126- treated rats, whereas the slight changes in the elution pattern of FSH pituitary isoforms suggest another level of endocrine disruption and an estrogen-like effect of PCB 153. Finally, serum LH and thyroxine appeared to be the only parameters altered by all three compounds. Thus, because of the regular occurrence and the sensitivity of these easily obtainable measurements, these results further support the measurement of serum LH and thyroxine as useful indicators of endocrine dysfunction, following acute exposure to xenobiotics, in adult male rats. ACKNOWLEDGMENTS The authors are grateful to Dr. V. Seligy and Dr. G. Cooke for their essential comments in the preparation of this manuscript; to W. Phan and C. Ulloa who contributed to some parts of this project as co-op students; to L. Casavant for excellent technical assistance; and to the National Hormone and Pituitary Program, the National Institute of Diabetes and Digestive and Kidney Diseases and to Dr. A. F. Parlow for providing assay reagents. This project was funded by Health Canada. REFERENCES Arey, B. J., Stevis, P. E., Deecher, D. C., Shen, E. S., Frail, D. E., Negro-Vilar, A., and Lopez, F. J. (1997). Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: A novel mechanism for transducing pleiotropic actions of FSH isoforms. Mol. Endocrinol. 11, 517–526. Baenziger, J. U., and Green, E. D. (1988). Pituitary glycoprotein hormone oligosaccharides: Structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin. Biochim. Biophys. Acta 947, 287–306. Bardin, C. W., and Peterson, R. E. (1967). Studies of androgen production by the rat: Testosterone and androstenedione content of blood. Endocrinology 80, 38 – 44. Barter, R. A., and Klaassen, C. D. (1994). Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats. Toxicol. Appl. Pharmacol. 128, 9 –17. Beitins, I. Z., and Padmanabhan, V. (1991). Bioactive follicle-stimulating hormone. Trends Endocrinol. Metab. 2, 145–151. Brouwer, A. (1998). Structure-dependent multiple interactions of polyhalogenated aromatic hydrocarbons with the thyroid hormone system. Organohalogen Compounds 37, 225–228. Brouwer, A., Morse, D. C., Lans, M. C., Schuur, A. G., Murk, A. J., KlassonWehler, E., Bergman, A., and Visser, T. J. (1998). Interactions of persistent environmental organohalogens with the thyroid hormone system: Mechanisms and possible consequences for animal and human health. Toxicol. Indust. Health 14, 59 – 84. Brown, J. L., and Chakraborty, P. K. (1991). Comparison of compensatory pituitary and testicular responses to hemicastration between prepubertal and mature rats. J. Androl. 12, 119 –125. Brown, J. L., Dahl, K. D., and Chakraborty, P. K. (1991). Effects of follicular fluid administration on serum bioactive and immunoreactive FSH concentrations and compensatory testosterone secretion in hemicastrated adult rats. J. Androl. 12, 221–225. Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., and Mayer, R. T. (1985). Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34, 3337–3345. Capen, C. C. (1995). Toxic responses of the endocrine system. In: Casarett and ENDOCRINE EFFECTS OF PCBs 126 AND 153 167 Doull’s Toxicology, the Basic Science of Poisons, 5th ed. (C. D. Klaassen, M. O. Amdur, and J. Doull, Eds.), pp. 617– 640. McGraw-Hill, New York. stabilization of plasma testosterone concentration in the hemicastrated rat. J. Endocr. 92, 225–229. Cemeroglu, A. P., Barkan, A. L., Kletter, G. B., Beitins, I. Z., and Foster, C. M. (1997). Changes in serum immunoreactive and bioactive growth hormone concentrations in boys with advancing puberty and in response to a 20-hour estradiol infusion. J. Clin. Endocrinol. Metab. 82, 2166 –2171. Frankel, A. I., and Wright, W. W. (1982). The hemicastrated rat: Definition of a model for the study of the regulation of testicular steroidogenesis. J. Endocr. 92, 213–223. Chu, I., Villeneuve, D. C., Yagminas, A., Lecavalier, P., Poon, R., Feeley, M., Kennedy, S. W., Seegal, R. F., Hakansson, H., Ahlborg, U. G., and Valli, V. E. (1994). Subchronic toxicity of 3,39,4,49,5-pentachlorobiphenyl in the rat. I. Clinical, biochemical, hematological, and histopathological changes. Fundam. Appl. Toxicol. 22, 457– 468. Cohen, H., Guillaumot, P., Sabbagh, I., and Bertrand, J. (1983). A new hypoprolactinemic rat strain. Prolactin, luteinizing hormone, follicle-stimulating hormone, testosterone and corticosterone levels in males and effects of two anesthetics. Biol. Reprod. 28, 122–127. Conn, P. M. (1996). Gonadotropin-releasing hormone action. In: Reproductive endocrinology, surgery, and technology. (E. Y. Adashi, J. A. Rock, and Z. Rosenwaks, Eds.), Vol. 1, pp 163–179. Lippincott-Raven, New York. Connor, K., Ramamoorthy, K., Moore, M., Mustain, M., Chen, I., Safe, S., Zacharewski, T., Gillesby, B., Joyeux, A., and Balaguer, P. (1997). Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: Structure-activity relationships. Toxicol. Appl. Pharmacol. 145, 111– 123. Cooke, G. M., Price, C. A. and Oko, R. J. (1999). Effects of in utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on serum androgens and steroidogenic enzyme activities in the male rat reproductive tract. J. Steroid Biochem. Mol. Biol. (in press). Cooper, T. G., and Waites, G. M. H. (1974). Testosterone in rete testis fluid and blood of rams and rats. J. Endocrinol. 62, 619 – 629. Croissandeau, G., Schussler, N., Grouselle, D., Pagesy, P., Rauch, C., Bayet, M. C., Peillon, F., and Le Dafniet, M. (1996). Evidence of thyrotropinreleasing hormone (TRH) gene expression in rat anterior pituitaries and modulation by estrogens of TRH-like immunoreactivity and TRH-elongated peptide contents. J. Endocrinol. 151, 87–96. Gharib, S. D., Wierman, M. E., Shupnik, M. A., and Chin, W. W. (1990). Molecular biology of the pituitary gonadotropins. Endocr. Rev. 11, 177–199. Gray, Jr. L. E., Ostby, J., Ferrell, J., Rehnberg, G., Linder, R., Cooper, R., Goldman, J., Slott, V., and Laskey, J. (1989). A dose-response analysis of methoxychlor-induced alterations of reproductive development and function in the rat. Fundam. Appl. Toxicol. 12, 92–108. Gray, Jr., L. E., Ostby, J., Marshall, R., and Andrews, J. (1993). Reproductive and thyroid effects of low-level polychlorinated biphenyl (aroclor I254) exposure. Fundam. Appl. Toxicol. 20, 288 –294. Hansen, L. G., Li, M.-H., Saeed, A., and Bush, B. (1995). Environmental polychlorinated biphenyls: Acute toxicity of landfill soil extract to female prepubertal rats. Arch. Environ. Contam. Toxicol. 29, 334 –343. Hassing, J. M., Kletter, G. B., Panson, H., Wood, R. I., Beitins, I. Z., Foster, D. L., and Padmanabhan, V. (1993). Pulsatile administration of gonadotropin-releasing hormone does not alter the follicle-stimulating hormone (FSH) isoform distribution pattern of pituitary or circulating FSH in nutritionally growth-restricted ovariectomized lambs. Endocrinology 132, 1527– 1536. Hileman, B. (1993). Concerns broaden over chlorine and chlorinated hydrocarbons. Chem. Eng. News, April 19, 11–20. Hirsh, A. V., Tyler, J. P. P., Landon, G., Pugh, R. C. B., Cameron, K. M., Pryor, J. P., and Collins, W. P. (1981). Testicular testosterone concentration, interstitial cell density and spermatogenesis in infertile men. Int. J. Androl. 4, 409 – 420. Jansen, H. T., Cooke, P. S., Porcelli, J., Liu, T.-C., and Hansen, L. G. (1993). Estrogenic and antiestrogenic actions of PCBs in the female rat: In vitro and In vivo studies. Reprod. Toxicol. 7, 237–248. Dahl, K. D., Stone, M. P. (1992). FSH isoforms, radioimmunoassays, bioassays, and their significance. J. Androl. 13, 11–22. Keel, B. A., and Schanbacher, B. D. (1987). Charge microheterogeneity of ovine follicle-stimulating hormone in rams and steroid-treated wethers. Biol. Reprod. 37, 786 –796. Desaulniers, D., Lussier, J. G., Goff, A. K., Bousquet, D., and Guilbault, L. A. (1995a). Follicular development and reproductive endocrinology during and after superovulation in heifers and mature cows displaying contrasting superovulatory responses. Theriogenology 44, 479 – 497. Kimura, N., Arai, K., Sahara, Y., and Suzuki, H. (1994). Estradiol transcriptionally and posttranscriptionally up-regulates thyrotropin-releasing hormone receptor messenger ribonucleic acid in rat pituitary cells. Endocrinology 134, 432– 440. Desaulniers, D., Lussier, J. G., Goff, A. K., Bousquet, D., and Guilbault, L. A. (1995b). Follicular development and reproductive endocrinology during a synchronized estrous cycle in heifers and mature cows displaying contrasting superovulatory responses. Domest. Anim. Endocrinol. 12, 117–131. Kodavanti, P. R. S., Shin, D., Tilson, H. A., and Harry, G. J. (1993). Comparative effects of two polychlorinated biphenyl congeners on Ca21-homeostasis in rat cerebellar granule cells. Toxicol. Appl. Pharmacol. 123, 97–106. Desaulniers, D., Poon, R., Phan, W., Leingartner, K., Foster, W. G., and Chu, I. (1997). Reproductive and thyroid hormone levels in rats following 90-day dietary exposure to PCB 28 (2,4,49-trichlorobiphenyl) or PCB 77 (3,39,4,49tetrachlorobiphenyl). Toxicol. Indust. Health 13, 627– 638. Kohn, M. C., Sewall, C. H., Lucier, G. W., and Portier, C. J. (1996). A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol. Appl. Pharmacol. 136, 29 – 48. Evans, W. S., Griffin, M. L., Yankov, V. I. (1996). The pituitary gonadotroph: Dynamics of gonadotropin release. In Reproductive Endocrinology, Surgery, and Technology. (E. Y. Adashi, J. A. Rock, Z. Rosenwaks, Eds.) Vol. 1. pp 181–210. Lippincott-Raven, New York. Foster, W. G. (1995). The reproductive toxicology of Great Lakes contamination. Environ. Health Perspect. 103, 63– 69. Foster, W. G., Pentick, J. A., McMahon, A., and Lecavalier, P. R. (1993a). Body distribution and endocrine toxicity of hexachlorobenzene (HCB) in the female rat. J. Appl. Toxicol. 13, 79 – 83. Foster, W. G., McMahon, A., Younglai, E. V., Hughes, E. G., and Rice, D. C. (1993b). Reproductive endocrine effects of chronic lead exposure in the male cynomolgus monkey. Reprod. Toxicol. 7, 203–209. Frankel, A. I., Mock, E. J. (1982). A study of the first eight hours in the Kojima, F. N., Cupp, A. S., Stumpf, T. T., Zalesky, D. D., Roberson, M. S., Werth, L. A., Wolfe, M. W., Kittok, R. J., Grotjan, H. E., and Kinder J. E. (1995). Effects of 17b-estradiol on distribution of pituitary isoforms of luteinizing hormone and follicle-stimulating hormone during the follicular phase of the bovine estrous cycle. Biol. Reprod. 52, 297–304. Krishnan, V., and Safe, S. (1993). Polychlorinated biphenyls (PCBs), dibenzop-dioxins (PCDDs), and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: Quantitative structure-activity relationships. Toxicol. Appl. Pharmacol. 120, 55– 61. Lamberts, S. W. J., and MacLeod, R. M. (1990). Regulation of prolactin secretion at the level of the lactotroph. Physiol. Rev. 70, 279 –318. Li, M.-H., and Hansen, L. G. (1997). Consideration of enzyme and endocrine interactions in the risk assessment of PCBs. Rev. Toxicol. 1, 71–156. Li, M.-H., Zhao, Y.-D., and Hansen, L. G. (1994). Multiple dose toxicokinetic 168 DESAULNIERS ET AL. influence on the estrogenicity of 2, 29, 4, 49, 5, 59-hexachlorobiphenyl. Bull. Environ. Contam. Toxicol. 53, 583–590. R. P., Calvo, F. O., and Vutyavanich, T. (1987). Structure-function relationships of gonadotropins. Recent. Prog. Horm. Res. 43, 383– 429. Lisboa, P. C., Curty, F. H., Moreira, R. M., and Pazosmoura, C. C. (1997). Effects of estradiol benzoate on 59-iodothyronine deiodinase activities in female rat anterior pituitary gland, liver and thyroid gland. Braz. J. Med. Biol. Res. 30, 1479 –1484. SAS Institute, Inc. (1992). Homovar.SAS Macro Function; Tests for Homogeneity of Variances. Latour, K. SAS Institute Inc., Cary, NC. Littell, R. C., Freund, R. J., Spector, P. C. (1991). Analyzing data with random effects. In: SAS System for Linear Models, 3rd ed. (SAS Institute Inc., Ed.), pp. 106 –114. SAS Institute Inc., Cary, NC. Liu, J., Liu, Y., Barter, R. A., and Klaassen, C. D. (1995). Alteration of thyroid homeostasis by UDP-glucuronosyltransferase inducers in rats: A doseresponse study. J. Pharmacol. Exp. Ther. 273, 977–985. Lussier, J. G., Matton, P., Guilbault, L. A., Grasso, F., Mapletoft, R. J., and Carruthers, T. D. (1994). Ovarian follicular development and endocrine responses in follicular-fluid treated and hemi-ovariectomized heifers. J. Reprod. Fertil. 102, 95–105. Maier, W. E., Kodavanti, P. R. S., Harry, G. J., and Tilson, H. A. (1994). Sensitivity of adenosine triphosphatases in different brain regions to polychlorinated biphenyl congeners. J. Appl. Toxicol. 14, 225–229. Matikainen, T., Ding, Y.-Q., Vergara, M., Huhtaniemi, I., Couzinet, B., and Schaison, G. (1992). Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J. Clin. Endocrinol. Metab. 75, 820 – 825. Matthews, C. H., Borgato, S., Beckpeccoz, P., Adams, M., Tone, Y., Gambino, G., Casagrande, S., Tedeschini, G., Benedetti, A., and Chatterjee, V. K. K. (1993). Primary amenorrhea and infertility due to a mutation in the betasubunit of follicle-stimulating hormone. Nat. Genet. 5, 83– 86. Schaaf, L., Leiprecht, A., Saji, M., Hubner, U., Usadel, K. H., and Kohn, L. D. (1997). Glycosylation variants of human TSH selectively activate signal transduction pathways. Mol. Cell. Endocrinol. 132, 185–194. Schultz, V. L., Boass, A., Garner, S. C., and Toverud, S. U. (1995). Several anesthetics, but not diethyl ether, cause marked elevation of serum parathyroid hormone concentration in rats. J. Bone. Miner. Res. 10, 1298 –1302. Schomburg, L., and Bauer, K. (1997). Regulation of the adenohypophyseal thyrotropin-releasing hormone-degrading ectoenzyme by estradiol. Endocrinology 138, 3587–3593. Seegal, R. F., Bush, B., and Shain, W. (1990). Lightly chlorinated orthosubstituted PCB congeners decrease dopamine in nonhuman primate brain and in tissue culture. Toxicol. Appl. Pharmacol. 106, 136 –144. Seo, B.-W., Li, M.-H., Hansen, L. G., Moore, R. W., Peterson, R. E., and Schantz, S. L. (1995). Effects of gestational and lactational exposure to coplanar polychlorinated biphenyl (PCB) congeners or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on thyroid hormone concentrations in weanling rats. Toxicol. Lett. 78, 253–262. Shain, W., Bush, B., and Seegal, R. (1991). Neurotoxicity of polychlorinated biphenyls: Structure-activity relationship of individual congeners. Toxicol. Appl. Pharmacol. 111, 33– 42. Simoni, M., Weinbauer, G. F., Chandolia, R. K., and Nieschlag, E. (1992). Microheterogeneity of pituitary follicle-stimulating hormone in male rats: Differential effects of the chronic androgen deprivation induced by castration or androgen blockade. J. Mol. Endocrinol. 9, 175–182. Medhamurthy, R., Suresh, R., Paul, S. S., and Moudgal, N. R. (1995). Evidence for follicle-stimulating hormone mediation in the hemiorchidectomyinduced compensatory increase in the function of the remaining testis of the adult male bonnet monkey (Macaca radiata). Biol. Reprod. 53, 525–531. Smith, P. L., and Baenziger, J. U. (1988). A pituitary N-acetylgalactosamine transferase that specifically recognizes glycoprotein hormones. Science 242, 930 –933. Moore, R. W., Potter, C. L., Theobald, H. M., Robinson, J. A., and Peterson, R. E. (1985). Androgenic deficiency in male rats treated with 2,3,7,8tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 79, 99 –111. Soto, A. M., Sonnenschein, C., Chung, K. L., Fernandez, M. F., Olea, N., and Olea Serrano, F. (1995). The E-SCREEN assay as a tool to identify estrogens: An update on estrogenic environmental pollutants. Environ. Health. Perspect. 103(Suppl 7), 113–122. Morse, D. C., Klasson, W. E., Wesseling, W., Koeman, J. H., and Brouwer, A. (1996). Alterations in rat brain thyroid hormone status following pre- and postnatal exposure to polychlorinated biphenyls (Aroclor 1254). Toxicol. Appl. Pharmacol. 136, 269 –279. Stanton, P. G., Burgon, P. G., Hearn, M. T. W., and Robertson, D. M. (1996). Structural and functional characterisation of hFSH and hLH isoforms. Molec. Cell. Endocrinol. 125, 133–141. Ness, D. K., Schantz, S. L., Moshtaghian, J., and Hansen, L. G. (1993). Effects of perinatal exposure to specific PCB congeners on thyroid hormone concentrations and thyroid histology in the rat. Toxicol. Lett. 68, 311–323. Stanton, P. G., Pozvek, G., Burgon, P. G., Robertson, D. M., and Hearn, M. T. W. (1993). Isolation and characterization of human LH isoforms. J. Endocrinol. 138, 529 –543. Newsome, H. W., Davies, D., and Doucet, J. (1995). PCB and organochlorine pesticides in Canadian human milk-1992. Chemosphere 30, 2143–2153. Stanton, P. G., Robertson, D. M., Burgon, P. G., Schmauk-White, B., and Hearn, M. T. W. (1992). Isolation and physiochemical characterization of human follicle-stimulating hormone isoforms. Endocrinology 130, 2820 – 2832. Phaneuf, D., DesGranges, J. L., Plante, N., and Rodrigue, J. (1995). Contamination of local wildlife following a fire at a polychlorinated biphenyls warehouse in St. Basile le Grand, Quebec, Canada. Arch. Environ. Contam. Toxicol. 28, 145–153. Phillips, D. J., and Wide, L. (1994). Serum gonadotropin isoforms become more basic after exogeneous challenge of gonadotropin-releasing hormone in children undergoing pubertal development. J. Clin. Endocrinol. Metab. 79, 814 – 819. Praputpittaya, C., and Kimura, F. (1987). Growth hormone secretion during long-term thiopental anesthesia in the immature rat. Psychoneuroendocrinology 12, 61– 66. Ruangwises, S., Bestervelt, L. L., Piper, D. W., Nolan, C. J., and Piper, W. N. (1991). Human chorionic gonadotropin treatment prevents depressed 17ahydroxylase/C17-20 lyase activities and serum testosterone concentrations in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rats. Biol. Reprod. 45, 143– 150. Ryan, R. J., Keutmann, H. T., Charlesworth, M. C., McCormick, D. J., Milius, Strutton, P. H., and Coen, C. W. (1996). Sodium pentobarbitone and the suppression of luteinizing hormone pulses in the female rat: The role of hypothermia. J. Neuroendocrinol. 8, 941–946. Stumpf, T. T., Roberson, M. S., Wolfe, M. W., Zalesky, D. D., Cupp, A. S., Werth, L. A., Kojima, N., Hejl, K., Kittok, R. J., Grotjan, H. E., and Kinder, J. E. (1992). A similar distribution of gonadotropin isohormones is maintained in the pituitary throughout sexual maturation in the heifer. Biol. Reprod. 46, 442– 450. van Birgelen, A. P. J. M., Smit, E. A., Kampen, I. M., Groeneveld, C. N., Fase, K. M., van der Kolk, J., Poiger, H., van den Berg, M., Koeman, J. H., and Brouwer, A. (1995). Subchronic effects of 2,3,7,8-TCDD or PCBs on thyroid hormone metabolism: Use in risk assessment. Eur. J. Pharmacol. 293, 77– 85. van Birgelen, A. P. J. M., van der Kolk, J., Poiger, H., van den Berg, M., and Brouwer, A. (1992). Interactive effects of 2,29,4,49,5,59-hexachlorobiphenyl ENDOCRINE EFFECTS OF PCBs 126 AND 153 and 2,3,7,8-tetrachlorodibenzo-P-dioxin on thyroid hormone, vitamin A, and vitamin K metabolism in the rat. Chemosphere 25, 1239 –1244. Veldhuis, J. D., and Dufau, M. L. (1993). Steroidal regulation of biologically active luteinizing hormone secretion in men and women. Hum. Reprod. 8, 84–96. Waddell, B. J., and Bruce, N. W. (1984). Production rate, metabolic clearance rate and blood concentration of progesterone in conscious and anaesthetized pregnant rats. J. Endocrinol. 102, 357–363. Wade, M. G., Desaulniers, D., Leingartner, K., and Foster, W. G. (1997). Interactions between endosulfan and dieldrin on estrogen-mediated processes in vitro and in vivo. Reprod. Toxicol. 11, 791–798. Waynforth, H. B., and Flecknell, P. A. (1992). Experimental and Surgical Technique in the Rat, 2nd ed. Academic Press, Toronto. Weiss, J., Axelrod, L., Whitcomb, R. W., Harris, P. E., Crowley, W. F., and Jameson, J. L. (1992). Hypogonadism caused by a single amino acid substitution in the b subunit of luteinizing hormone. N. Engl. J. Med. 326, 179–183. 169 Wide, L., and Bakos, O. (1993). More basic forms of both human folliclestimulating hormone and luteinizing hormone in serum at midcycle compared with the follicular or luteal phase. J. Clin. Endocrinol. Metab. 76, 885– 889. Wilson, C. A., Leigh, A. J., and Chapman, A. J. (1990). Review: Gonadotrophin glycosylation and function. J. Endocrinol. 125, 3–14. Wong, P. W., Joy, R. M., Albertson, T. E., Schantz, S. L., and Pessah, I. N. (1997). Ortho-substituted 2,29,3,59,6-pentachlorobiphenyl (PCB 95) alters rat hippocampal ryanodine receptors and neuroplasticity in vitro: Evidence for altered hippocampal function. Neurotoxicology 18, 443– 456. Zambrano, E., Olivares, A., Mendez, J. P., Guerrero, L., Diaz-cueto, L., Veldhuis, J. D., and Ulloa-Aguirre, A. (1995). Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle. J. Clin. Endocrinol. Metab. 80, 1647–1656.